James Quigley
Stock Analyst at Goldman Sachs
(1.09)
# 3,833
Out of 5,182 analysts
26
Total ratings
33.33%
Success rate
-0.76%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Downgrades: Neutral | $63 → $41 | $39.32 | +4.27% | 2 | Mar 2, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $73 → $127 | $89.87 | +41.32% | 7 | Dec 9, 2025 | |
| NVS Novartis AG | Downgrades: Sell | $119 → $118 | $153.38 | -23.07% | 2 | Sep 12, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $47.64 | +36.44% | 1 | Mar 21, 2025 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $8.52 | +23.31% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $28.86 | +38.62% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $3.12 | +412.82% | 3 | Jun 23, 2023 |
Novo Nordisk
Mar 2, 2026
Downgrades: Neutral
Price Target: $63 → $41
Current: $39.32
Upside: +4.27%
Kymera Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $73 → $127
Current: $89.87
Upside: +41.32%
Novartis AG
Sep 12, 2025
Downgrades: Sell
Price Target: $119 → $118
Current: $153.38
Upside: -23.07%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $47.64
Upside: +36.44%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $8.52
Upside: +23.31%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $28.86
Upside: +38.62%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $3.12
Upside: +412.82%